ATRA treatment leads to an increase in BCMA transcript and protein expression in MM cell lines and primary MM cells and enhances the efficacy of BCMA-CART, and co-treatment of MM cells with ATRA and the γ-secretase inhibitor, crenigacestat, further increases BCMA expression and enhances the efficacy of BCMA-CART (García-Guerrero et al., 2023). This evidence concerns the gene CARTPT and Miyoshi myopathy.